These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
245 related articles for article (PubMed ID: 27836119)
61. Five-year clinical outcomes of scanning carbon-ion radiotherapy for prostate cancer. Takakusagi Y; Koge H; Kano K; Shima S; Tsuchida K; Mizoguchi N; Yoshida D; Kamada T; Katoh H PLoS One; 2024; 19(3):e0290617. PubMed ID: 38457424 [TBL] [Abstract][Full Text] [Related]
62. Intensity-modulated radiation therapy for prostate cancer: late morbidity and results on biochemical control. De Meerleer GO; Fonteyne VH; Vakaet L; Villeirs GM; Denoyette L; Verbaeys A; Lummen N; De Neve WJ Radiother Oncol; 2007 Feb; 82(2):160-6. PubMed ID: 17222931 [TBL] [Abstract][Full Text] [Related]
63. Five-Year Survival Outcomes After Carbon-Ion Radiotherapy for Operable Stage I NSCLC: A Japanese National Registry Study (J-CROS-LUNG). Kubo N; Suefuji H; Nakajima M; Tokumaru S; Okano N; Yoshida D; Suzuki O; Ishikawa H; Satouchi M; Nakayama H; Shimizu K; Shioyama Y J Thorac Oncol; 2024 Mar; 19(3):491-499. PubMed ID: 37924974 [TBL] [Abstract][Full Text] [Related]
64. Cost-effectiveness of carbon ion radiation therapy for locally recurrent rectal cancer. Mobaraki A; Ohno T; Yamada S; Sakurai H; Nakano T Cancer Sci; 2010 Aug; 101(8):1834-9. PubMed ID: 20500516 [TBL] [Abstract][Full Text] [Related]
65. Carbon ion radiation therapy for prostate cancer: results of a prospective phase II study. Ishikawa H; Tsuji H; Kamada T; Yanagi T; Mizoe JE; Kanai T; Morita S; Wakatsuki M; Shimazaki J; Tsujii H; Radiother Oncol; 2006 Oct; 81(1):57-64. PubMed ID: 16971008 [TBL] [Abstract][Full Text] [Related]
66. Moderate Hypofractionation with Simultaneous Integrated Boost in Prostate Cancer: Long-term Results of a Phase I-II Study. Di Muzio NG; Fodor A; Noris Chiorda B; Broggi S; Mangili P; Valdagni R; Dell'Oca I; Pasetti M; Deantoni CL; Chiara A; Berardi G; Briganti A; Calandrino R; Cozzarini C; Fiorino C Clin Oncol (R Coll Radiol); 2016 Aug; 28(8):490-500. PubMed ID: 26961088 [TBL] [Abstract][Full Text] [Related]
67. Risk factors of late rectal bleeding after carbon ion therapy for prostate cancer. Ishikawa H; Tsuji H; Kamada T; Hirasawa N; Yanagi T; Mizoe JE; Akakura K; Suzuki H; Shimazaki J; Tsujii H Int J Radiat Oncol Biol Phys; 2006 Nov; 66(4):1084-91. PubMed ID: 16979840 [TBL] [Abstract][Full Text] [Related]
68. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. Zelefsky MJ; Fuks Z; Hunt M; Lee HJ; Lombardi D; Ling CC; Reuter VE; Venkatraman ES; Leibel SA J Urol; 2001 Sep; 166(3):876-81. PubMed ID: 11490237 [TBL] [Abstract][Full Text] [Related]
69. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial. Aluwini S; Pos F; Schimmel E; Krol S; van der Toorn PP; de Jager H; Alemayehu WG; Heemsbergen W; Heijmen B; Incrocci L Lancet Oncol; 2016 Apr; 17(4):464-474. PubMed ID: 26968359 [TBL] [Abstract][Full Text] [Related]